Citations

Clear

949 citation(s) found for "Li, Bryan".

Relationship between taxane-induced neuropathy and clinical outcomes after adjuvant chemotherapy.
Schneider, Bryan P. , Wang, M. , Martino, Silvana, Jones, Vicky, Perez, Edith A. , Saphner, Thomas J. , Wood, W. C. , Davidson, Nancy E. , Sparano, J. A., Stearns, Vered , Wolff, Antonio C. , Sledge, George W.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 29 | Issue: 27_suppl | Pages: 270-270

10.1200/jco.2011.29.27_suppl.270 Get It

270 Background: Neuropathy is a common and potentially enduring and disabling complication of adjuvant taxane therapy. Recent studies have identified candidate host single nucleotide polymorphisms (SNPs) associated with taxane-induced neuropathy (Schneider et al. ASCO 2011, abstr. 1000). We therefore sought to determine whether neuropathy was associated with breast cancer recurrence. Methods: This study included 4,950 eligible women with axillary lymph node positive or high-risk node-negative breast cancer who received up to 4 cycles of AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2) every 3 weeks, followed by either: (1) paclitaxel 175 mg/m2 every 3 weeks x 4 (P3), (2) paclitaxel 80 mg/m2 weekly x 12 (P1), (3) docetaxel 100 mg/m2 every 3 weeks x 4 (D3), or (4) docetaxel 35 mg/m2 weekly x 12 (D1). Chemotherapy doses were based on actual body weight. Cox proportional hazards model were used to determine the relationship between neuropathy and disease free survival (DFS) and overall survival (OS) treating neuropathy status as a time dependent covariate and using a landmark analysis. Results: Of 4,702 patients who received at least 1 taxane dose, grade 2-4 neuropathy developed in 20%, 27%, 16%, and 16% in the P3, P1, D3, and D1 arms, respectively. In a model including age, tumor size, nodal status, treatment arm, neuropathy, and the neuropathy- treatment interaction, there was no relationship between neuropathy and DFS and OS in the entire population, for any of the individual treatment arms, or for any breast cancer subtypes, whether analyzed as a time-dependent covariate or using a landmark analysis. Baseline covariates associated with an increase rate of neuropathy included black race (25% vs. 19% grade 2-4, p=0.02) and obesity (21% vs. 19%, p=0.04), but not age. Conclusions: There was no association between taxane-induced neuropathy and DFS or OS in patients treated with contemporary AC-taxane therapy, including weekly paclitaxel. These findings show that taxane-induced neuropathy is not associated with outcome, thus suggesting that validation of SNPs predictive of neuropathy may be useful in identifying patients at higher risk for neuropathy but not taxane benefit and thereby improve therapeutic individualization.
Bortezomib induces oxidative stress and apoptosis that are synergistically enhanced by a Bcl-2 inhibitor in human pancreatic cancer cells
Freeburg, E. N., Huang, Der‐Yi, Yeung, Bryan K. S. , Sinicrope, Frank A.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 3161-3161

10.1200/jco.2005.23.16_suppl.3161 Get It

Speaker Introductions at Internal Medicine Grand Rounds: Forms of Address Reveal Gender Bias
Files, Julia A. , Mayer, Anita P. , Ko, Marcia G., Friedrich, Patricia , Jenkins, Marjorie , Bryan, Michael , Vegunta, Suneela , Wittich, Christopher M. , Lyle, Melissa , Melikian, Ryan, Duston, Trevor, Bryan, Michael J, Lyle, Melissa A. , Chang, Yu‐Hui H., Chang, Yu‐Hui , Hayes, Sharonne N.

Mayo Clinic

Journal of Women's Health | February 16, 2017 | Volume: 26 | Issue: 5 | Pages: 413-419

10.1089/jwh.2016.6044 | PMID 28437214 Get It

Molecular Biomarkers for the Evaluation of Colorectal Cancer
Sepulveda, Antonia R. , Allegra, Carmen J. , Grody, Wayne W., Cushman‐Vokoun, Allison M. , Funkhouser, William K., Kopetz, Scott , Lindor, Noralane M. , Minsky, Bruce D. , Monzon, Federico A. , Singh, Veena , Clark, Jennifer , Colasacco, Carol , Temple‐Smolkin, Robyn , Ventura, Christina B., Nowak, Jan A. , Hamilton, Stanley R. , Lieu, Christopher H. , Sargent, Daniel J. , Willis, Joseph , Rumble, R. Bryan , Kopetz, Scott

Mayo Clinic

American Journal of Clinical Pathology | February 6, 2017 | Volume: 147 | Issue: 3 | Pages: 221-260

10.1093/ajcp/aqw209 | PMID 28165529 Get It

Abstract Objectives: To develop evidence-based guideline recommendations through a systematic review of the literature to establish standard molecular biomarker testing of colorectal cancer (CRC) tissues to guide epidermal growth factor receptor (EGFR) therapies and conventional chemotherapy regimens. Methods: The American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology convened an expert panel to develop an evidence-based guideline to establish standard molecular biomarker testing and guide therapies for patients with CRC. A comprehensive literature search that included more than 4,000 articles was conducted. Results: Twenty-one guideline statements were established. Conclusions: Evidence supports mutational testing for EGFR signaling pathway genes, since they provide clinically actionable information as negative predictors of benefit to anti-EGFR monoclonal antibody therapies for targeted therapy of CRC. Mutations in several of the biomarkers have clear prognostic value. Laboratory approaches to operationalize CRC molecular testing are presented.
Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology
Sepulveda, Antonia R. , Allegra, Carmen J. , Grody, Wayne W., Cushman‐Vokoun, Allison M. , Funkhouser, William K., Kopetz, Scott , Lindor, Noralane M. , Minsky, Bruce D. , Monzon, Federico A. , Singh, Veena , Clark, Jennifer , Temple‐Smolkin, Robyn , Ventura, Christina B., Nowak, Jan A. , Hamilton, Stanley R. , Lieu, Christopher H. , Sargent, Daniel J. , Willis, Joseph , Colasacco, Carol , Rumble, R. Bryan , Kopetz, Scott

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 6, 2017 | Volume: 141 | Issue: 5 | Pages: 625-657

10.5858/arpa.2016-0554-cp | PMID 28165284 Get It

Objectives.— To develop evidence-based guideline recommendations through a systematic review of the literature to establish standard molecular biomarker testing of colorectal cancer (CRC) tissues to guide epidermal growth factor receptor (EGFR) therapies and conventional chemotherapy regimens. Methods.— The American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology convened an expert panel to develop an evidence-based guideline to establish standard molecular biomarker testing and guide therapies for patients with CRC. A comprehensive literature search that included more than 4,000 articles was conducted. Results.— Twenty-one guideline statements were established. Conclusions.— Evidence supports mutational testing for EGFR signaling pathway genes, since they provide clinically actionable information as negative predictors of benefit to anti-EGFR monoclonal antibody therapies for targeted therapy of CRC. Mutations in several of the biomarkers have clear prognostic value. Laboratory approaches to operationalize CRC molecular testing are presented.
Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells
Tivnan, Amanda , Heilinger, Tatjana, Ramsey, Joanne M. , O’Connor, Gemma, Pokorny, Jenny L. , Stringer, Brett W. , Day, Bryan W. , Kim, Ella L., Lode, Holger N. , Cryan, Sally‐Ann , Sarkaria, Jann N. , Boyd, Andy , Kim, Ella, Prehn, Jochen H.M.

Mayo Clinic

Oncotarget | February 4, 2017 | Volume: 8 | Issue: 10 | Pages: 16605-16620

10.18632/oncotarget.15073 | PMID 28178667 Get It

American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to
Haugen, Bryan R. , Sawka, Anna M. , Alexander, Erik K. , Bible, Keith C. , Doherty, Gerard M. , Mandel, Susan J., Pacini, Furio , Schlumberger, Martin, Schuff, Kathryn G., Somerset, Hilary, Steward, David L. , Wartofsky, Leonard , Williams, Michelle D. , Caturegli, Patrizio , Morris, John C., Nassar, Aziza , Sherman, Steven I. , Sosa, Julie Ann

Mayo Clinic

Thyroid | January 23, 2017 | Volume: 27 | Issue: 4 | Pages: 481-483

10.1089/thy.2016.0628 | PMID 28114862 Get It

Implementation of a Comprehensive Population Health Management Model
Matthews, Marc R. , Stroebel, Robert J. , Wallace, Mark R. , Bryan, Michael , Swanson, Jill A., Allen, Summer V. , Bunkers, Kari S., Bryan, Michael J, Matthews, Marc R

Mayo Clinic

Population Health Management | January 18, 2017 | Volume: 20 | Issue: 5 | Pages: 337-339

10.1089/pop.2016.0130 | PMID 28099067 Get It

Immunologic Studies on Cancer of the Upper Aerodigestive Tract
Gustafson, Ray O., Neel, H. Bryan, Pearson, Gary R.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | January 5, 2017 | Volume: 90 | Issue: 1 | Pages: 52-57

10.1177/019459988209000110 | PMID 6283457 Get It

Natural killing (NK) may play an important role in immunosurveillance against virus‐infected and malignant cells. This study has demonstrated that the NK susceptibility of Epstein‐Barr virus (EBV)‐related cell lines increases with increased viral expression within the cells. This finding has implications for surveillance against, and treatment of, EBV‐related disease. Additionally, preliminary studies of the NK status of head and neck cancer patients reveal a distinct clustering of the patients into either groups of high or low NK reactivity. This clustering phenomenon may have a correlation with patient prognosis.
Immunologic Detection of Occult Primary Cancer of the Head and Neck
Neel, H. Bryan, Pearson, Gary R., Weiland, Louis H., Taylor, William F., Goepfert, Helmuth

Mayo Clinic

Otolaryngology–Head and Neck Surgery | January 5, 2017 | Volume: 89 | Issue: 2 | Pages: 230-234

10.1177/019459988108900217 | PMID 6264367 Get It

Because antibody titers against Epstein‐Barr virus (EBV) antigens often are elevated in patients with active undifferentiated and nonkeratinizing nasopharyngeal carcinoma, anti‐EBV serologic tests have been applied as a diagnostic aid in patients who have metastatic lymphadenopathy in the neck without an obvious source. In this study of 44 patients, the serologic testing procedure proved useful in identifying six patients with nasopharyngeal carcinoma that was initially occult but was eventually confirmed by biopsy.